Jonas Odgaard Petersen
@OdgaardJonas
Followers
245
Following
1K
Media
3
Statuses
50
Co-founder of Ousia Pharma. Postdoctoral fellow working on development of novel anti-obesity medicines. Chemistry.
Copenhagen, Denmark
Joined January 2019
Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in @Nature today! https://t.co/LLDn8oVbph 1/7 🧵
nature.com
Nature - Unimolecular integration of NMDA receptor antagonism with GLP-1 receptor agonism effectively reverses obesity, hyperglycaemia and dyslipidaemia in rodent models of metabolic disease.
8
31
170
1/8 🧠 New review from the lab in @CellCellPress: Brain Control of Energy Homeostasis We explore how central nervous system circuits regulate energy balance, and how this informs the development of next-generation obesity pharmacotherapies. 🔗
cell.com
Advances in mapping how the brain regulates energy homeostasis, together with progress in peptide-based pharmacotherapy, highlight emerging opportunities for obesity treatment with the potential to...
8
45
151
Thrilled to have contributed to this snapshot article on "Brain-Targeting Anti-Obesity Medications" appearing today in @Cell_Metabolism on #WorldObesityDay.
On #WorldObesityDay, we have contributed a SnapShot to a special Issue on Obesity in @Cell_Metabolism covering brain actions of the current and emerging weight loss drugs. @OdgaardJonas @JohansenVBI
@UCPH_health Free access link: https://t.co/87NUv3EfPg
0
0
6
1/4 New paper out in @MolMetab in which we show that calorie restriction before starting treatment with semaglutide or tirzepatide pushes maximum achievable weight loss by ~8%
1
11
39
A few months back, we published a study in @ScienceAdvances demonstrating the potential of targeting postsynaptic glutamate receptor scaffolding proteins, such as PSD-95, for sustained weight loss. Headed by @nicolefadahunsi, @OdgaardJonas and @Met_Sop
science.org
Scaffolding proteins PICK1 and PSD-95 are genetically linked to obesity and therapeutic targets for sustained weight loss.
1
3
40
Big day for the lab as our latest paper is out in Nature Chemical Biology @nchembio on identifying the oxybipins as new OSBP inhibitors, as well as their mechanism of action and therapeutic applications! https://t.co/oP2HIcDiUT 1/n
nature.com
Nature Chemical Biology - Oxybipins were identified as potent selective inhibitors of oxysterol-binding protein, promoting Golgi fragmentation, inhibiting retrograde trafficking and attenuating...
6
28
130
Research Highlight in @NatRevDrugDisc covering our recent paper on targeted NMDA receptor antagonism for obesity treatment
nature.com
Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com
0
6
32
7/7 Kudos to all the people involved in this massive collaborative effort from the labs of @ClemmensenC @stromgaardlab @Froelund_lab @tunepers @thewilliamslab @KAKohlmier @atul_deshmukh1 @Thue_Schwartz and @MortenBThomsen from @Metabolcenter at @koebenhavns_uni @UCPH_health
1
1
6
6/7 Check out the informative thread by @ClemmensenC. It has been absolutely amazing working on this piece together, and I am excited to continue working on the next-generation of compounds in @OusiaPharma together with @BueKlein with support from @BioCPH and @Innofond .
1
0
5
5/7 Through intense medicinal chemistry and in vivo pharmacology optimization, we succeeded in the development of a stability optimized conjugate. In the study we find that GLP-1R and NMDAR pharmacology synergize to effectively reverse metabolic disorders in mice.
1
0
6
4/7 To safely harvest the appetite-modulating effects of NMDAR antagonism, we engineered a first-in-class dual-acting compound that chemically combines GLP-1R agonism and NMDAR antagonism in a single Trojan horse like molecule.
1
0
7
3/7 Inspired by these findings, we embarked on the idea of therapeutically leveraging NMDAR pharmacology for treatment of obesity. We found that NMDAR antagonism potently lowers body weight in obese mice, but that the therapeutic utility is hampered by intolerable adverse effects
2
0
6
2/7 Genome-wide association studies inform that the CNS should be regarded as a primary target for obesity treatment, and highlights glutamatergic signaling and NMDA receptor-related neuroplasticity in body weight homeostasis. https://t.co/PFf7Prav5u
1
0
4
Exciting news! My main paper for my PhD in the @ClemmensenC lab with @pranea is now published in @naturecomms! 🎉 It delves into how the body is naturally defended against excessive weight gain. A🧵👇#obesityresearch 1/11
nature.com
Nature Communications - Overfeeding triggers a mechanistically ill-defined compensatory response that counteracts weight gain. Here, the authors show that the defence against overfeeding is...
10
33
134
🏆 I am deeply honored to be one of the recipients of the UCPH: BII Life Science Innovation Award 2023 at the SUND Innovation Day 2023. It was truly exciting to showcase our innovative solutions that were born in the @ClemmensenC lab and later incorporated to @OusiaPharma.
We couldn't be more proud of Postdoc @OdgaardJonas and PhD Student @SassFrederike for being among the winners of the UCPH: @BioCPH Life Science Innovation Award at the @UCPH_health Innovation day! 🏆 CBMR is committed to translating its discoveries to accelerate the prediction,
0
4
29
Fascinating developments in weight loss drugs! Eli Lilly's triagonist phase 2 data: Nearly half of participants achieved >25% weight loss, with a quarter surpassing the impressive >30% mark. The bar continues to rise for incretin-based therapies. https://t.co/iRg7RsoRFq
nejm.org
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effe...
1
12
67
The first Danish peptide symposium takes place in Copenhagen on August 31 https://t.co/KzeBeCUX1f
1
16
68
A drug originally developed to treat #diabetes and severe overweight may also be able to help people with #nicotine dependence 💊🚫🚬 Read more about the discovery by the @ClemmensenC Group, which was recently published in @CellReports 👇 https://t.co/vpoW0ocOhT
cbmr.ku.dk
A drug that was originally developed to treat diabetes and severe overweight might also help people with nicotine dependence, concludes new research from the University of Copenhagen.
1
1
8
Our latest research sheds light on the intricate cross talk between GLP-1 (liraglutide) and nicotine biology. As the clinical use of GLP-1 based drugs increases, understanding the interaction with nicotine/tobacco consumption becomes increasingly relevant
cell.com
Falk et al. demonstrate that nicotine potentiates GLP-1 receptor agonist-driven weight loss in obese mice. Co-administration of nicotine and liraglutide triggers neuronal activity in the hypothalam...
9
27
137